Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
7
×
detroit blog main
detroit top stories
7
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
pfizer
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
biogen
cancer
celgene
eli lilly
fda
investing
abbvie
alzheimer's disease
amgen
astrazeneca
What
bio
roundup
7
×
drug
news
week
alzheimer’s
approved
biogen
biotech
days
fda
growing
nash
adu
aducanumab
advantages
alliance
amyloid
angst
annual
assessed
attention
august
bagged
bar
beats
bids
billions
biogen’s
brammer
brings
bristol
busy
buy
calls
changing
color
communities
companies
complicated
Language
unset
Current search:
roundup
×
" bristol-myers squibb "
×
" detroit top stories "
×
pfizer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More